The wet AMD market is dominated by three therapies—Roche / Genentech / Novartis’s Lucentis, approved for wet AMD, Roche / Genentech / Chugai’s Avastin, approved for cancer but commonly compounded and used off-label for wet AMD, and Regeneron / Bayer HealthCare / Santen’s Eylea, which has experienced strong and continued uptake at the expense of the other VEGF inhibitors. Although the majority of AMD patients are diagnosed with the dry form of AMD, management of this disease type is limited to minimally effective vitamin formulations because no prescription pharmacotherapies are approved for this large and underserved subpopulation. While the bulk of emerging therapies target wet AMD patients because the pathology presents clearer drug targets, there are a small number of novel therapies being tested in patients with the dry form of AMD—an indication that has been plagued by several Phase III failures.
Questions Answered:
Product Description:
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 18 country-specific interviews with thought-leading retinal specialists. Supported by survey data collected for this and other DRG research.
Epidemiology: Total prevalence of late AMD by country, segmented by GA and wet AMD subpopulations, including diagnosed and drug-treated rates.
Forecast: Ten-year, annualized, drug-level sales and patient share of key GA and wet AMD therapies, segmented by brands / biosimilars and epidemiological subpopulations.
Emerging therapies: Phase III/PR: 7 drugs; Phase II/III: 1 drug; key early-phase therapies.